AXSM insider buying and SEC filings, explained
Axsome Therapeutics, Inc. · CIK 1579428
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$134.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 3, 2026 | Planned (10b5-1) | Mark L. Jacobson (President / COO) sold 10,000 shares at about $208.65 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 5–6, 2026 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 49,664 shares between Aug 5 and Aug 6 at about $212.19 ($10.5M), marked as a 10b5-1 plan trade. Holdings down 87% to 7,229 shares. | SEC filing Filed Aug 7, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 49,666 shares at about $240.25 ($11.9M), marked as a 10b5-1 plan trade. Holdings down 87% to 7,229 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 10–11, 2026 | Planned (10b5-1) | Roger Jeffs (Director) sold 572 shares between Jun 10 and Jun 11 at about $247.65 ($142K), marked as a 10b5-1 plan trade. Holdings down 1% to 58,367 shares. | SEC filing Filed Jun 11, 2026 |
| Jun 9–10, 2026 | Planned (10b5-1) | Susan Mahony (Director) sold 600 shares between Jun 9 and Jun 10 at about $241.70 ($145K), marked as a 10b5-1 plan trade. Holdings down 42% to 829 shares. | SEC filing Filed Jun 10, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | Mark Coleman (Director) sold 643 shares at about $249.00 ($160K), marked as a 10b5-1 plan trade. Holdings down 2% to 30,389 shares. | SEC filing Filed Jun 10, 2026 |
| Jun 9, 2026 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 49,670 shares at about $241.01 ($12.0M), marked as a 10b5-1 plan trade. Holdings down 87% to 7,229 shares. | SEC filing Filed Jun 9, 2026 |
| Jun 9, 2026 | Planned (10b5-1) | Nick Pizzie (CFO) sold 33,000 shares at about $240.09 ($7.9M), marked as a 10b5-1 plan trade. Holdings down 43% to 42,867 shares. | SEC filing Filed Jun 9, 2026 |
| May 29–Jun 2, 2026 | Planned (10b5-1) | Mark Coleman (Director) sold 17,537 shares between May 29 and Jun 2 at about $229.20 ($4.0M), marked as a 10b5-1 plan trade. Holdings down 37% to 29,603 shares. | SEC filing Filed Jun 2, 2026 |
| May 4–5, 2026 | Planned (10b5-1) | Mark L. Jacobson (President / COO) sold 4,750 shares between May 4 and May 5 at about $227.95 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 5, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | Ari Maizel (Chief Commercial Officer) sold 7,500 shares at about $182.42 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 23, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Mark Coleman (Director) sold 25,000 shares at about $161.11 ($4.0M), marked as a 10b5-1 plan trade. Holdings down 35% to 47,140 shares. | SEC filing Filed Feb 27, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Mark L. Jacobson (President / COO) sold 35,378 shares at about $161.88 ($5.7M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Feb 27, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 32,410 shares at about $185.60 ($6.0M), marked as a 10b5-1 plan trade. Holdings down 82% to 7,229 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Nick Pizzie (CFO) sold 12,000 shares at about $187.92 ($2.3M), marked as a 10b5-1 plan trade. Holdings down 22% to 42,588 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 21, 2026 | Planned (10b5-1) | Ari Maizel (Chief Commercial Officer) sold 7,500 shares at about $184.44 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 23, 2026 |
| Jan 5–7, 2026 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 139,414 shares between Jan 5 and Jan 7 at about $171.30 ($23.9M), marked as a 10b5-1 plan trade. Holdings down 95% to 7,229 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 31, 2025 | Planned (10b5-1) | Mark E Saad (Director) sold 37,577 shares at about $165.18 ($6.2M), marked as a 10b5-1 plan trade. Holdings down 79% to 10,002 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 2–4, 2025 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 79,973 shares between Dec 2, 2025 and Dec 4, 2025 at about $145.66 ($11.6M), marked as a 10b5-1 plan trade. Holdings down 92% to 7,229 shares. | SEC filing Filed Dec 4, 2025 |
| Nov 3–5, 2025 | Planned (10b5-1) | Herriot Tabuteau (CEO and Director) sold 163,939 shares between Nov 3, 2025 and Nov 5, 2025 at about $133.07 ($21.8M), marked as a 10b5-1 plan trade. Holdings down 96% to 7,229 shares. | SEC filing Filed Nov 5, 2025 |
36 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 2, 2026, 7:05 AM ET 8-K | Earnings released (Item 2.02) Other event (Item 8.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow AXSM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.